Table 1.
Baseline characteristics of patients receiving Ate/Bev or Len before and after PSM
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Ate/Bev (n=80) | Len (n=266) | P-value | Ate/Bev (n=73) | Len (n=142) | P-value | |
| Male sex, n (%) | 61 (76.3) | 201 (75.6) | 0.9 | 55 (75.3) | 103 (72.5) | 0.659 |
| Age (years) | 61.6±11.6 | 65.4±11.4 | 0.012 | 63.2±10.5 | 63.2±11.4 | 0.987 |
| Child-Pugh class | ||||||
| A, n (%) | 67 (85.9) | 249 (94.3) | 0.014 | 64 (87.7) | 131 (92.3) | 0.273 |
| B, n (%) | 11 (14.1) | 15 (5.7) | 9 (12.3) | 11 (7.7) | ||
| Viral etiology, n (%) | 61 (76.3) | 199 (74.8) | 0.794 | 55 (75.3) | 106 (74.6) | 0.911 |
| HBV infection, n (%) | 51 (63.7) | 137 (51.5) | 45 (61.6) | 78 (54.9) | 0.346 | |
| HCV infection, n (%) | 14 (17.9) | 67 (25.2) | 14 (19.2) | 31 (21.8) | 0.651 | |
| ALBI grade | ||||||
| 1, n (%) | 36 (46.2) | 151 (57) | 0.178 | 35 (48.6) | 65 (45.8) | 0.676 |
| 2, n (%) | 38 (48.7) | 107 (40.4) | 33 (45.8) | 72 (50.7) | ||
| 3, n (%) | 4 (5.1) | 7 (2.6) | 4 (5.6) | 5 (3.5) | ||
| BCLC stage | ||||||
| B, n (%) | 10 (12.5) | 53 (19.9) | 0.131 | 10 (13.7) | 17 (12) | 0.717 |
| C, n (%) | 70 (87.5) | 213 (80.1) | 63 (86.3) | 125 (88) | ||
| EHM, n (%) | 40 (50) | 144 (45.9) | 0.516 | 35 (47.9) | 65 (45.8) | 0.763 |
| MVI, n (%) | 44 (55) | 117 (44) | 0.083 | 41 (56.2) | 74 (52.1) | 0.573 |
| Vp4, n (%) | 20 (25) | 34 (12.8) | 0.008 | 18 (24.7) | 24 (16.9) | 0.174 |
| Tumor size >6 cm, n (%) | 47 (58.8) | 107 (40.2) | 0.003 | 43 (58.9) | 76 (53.5) | 0.578 |
| BMI, kg/m2 | 24.5±3.2 | 24.7±4 | 0.506 | 24.4±3.2 | 24.3±3.6 | 0.812 |
| AST, IU/L | 76.5±48.6 | 63.6±51.9 | 0.045 | 73.4±47.6 | 73.7±61.6 | 0.973 |
| ALT, IU/L | 51.9±36 | 52.9±63 | 0.864 | 52.6±37.3 | 59.9±81 | 0.17 |
| AFP, ng/ml | 8802±20738 | 6753±18331 | 0.428 | 7553±21568 | 7281±18006 | 0.441 |
| AFP≥400, n (%) | 34 (43) | 91 (34.2) | 0.152 | 31 (42.5) | 56 (39.4) | 0.668 |
| NLR | 4.5±2.9 | 3.8±2.5 | 0.057 | 4.5±3.0 | 3.9±2.7 | 0.181 |
| NLR>3, N (%) | 52 (65) | 120 (52.9) | 0.06 | 46 (63) | 59 (50) | 0.079 |
| PLR | 4.6±3.5 | 3.9±2.6 | 0.228 | 189.5±119 | 169.9±99 | 0.243 |
| PLR>230, N (%) | 25 (45.5) | 42 (38.9) | 0.421 | 16 (21.9) | 26 (22.2) | 0.961 |
| Concurrent treatment, n (%) | 16 (20) | 108 (40.6) | 0.001 | 16 (21.9) | 65 (45.8) | 0.001 |
| Pembrolizumab/Nivolumab | 0 | 17/8 | 0 | 12/5 | ||
| Radiotherapy | 2 | 23 | 2 | 16 | ||
| TACE | 4 | 19 | 4 | 8 | ||
| Proton bean radiotherapy | 9 | 18 | 9 | 12 | ||
| Post treatment, n (%) | 43 (53.8) | 107 (46.9) | 0.294 | 40 (54.8) | 54 (43.9) | 0.14 |
| Treatment stop, n (%) | 75 (93.8) | 223 (83.8) | 0.024 | 68 (93.2) | 120 (84.5) | 0.07 |
Abbreviations: AFP, alpha-fetoprotein; ALBI grade, albumin-bilirubin grade; ALT, alanine aminotransferase; AST, aspartate transaminase; Ate/Bev, Atezolizumab plus Bevacizumab; BCLC stage, Barcelona Clinic Liver Cancer stage; BMI, body mass index; EHM, extra-hepatic metastasis; Len, Lenvatinib; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; PSM, propensity score matching; TACE, trans-arterial chemoembolization; Vp4, main portal vein invasion or bilateral portal vein invasion.